Novel promising agents for the treatment of ITP

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, highlights exciting developments in treatments for patients with chronic immune thrombocytopenia (ITP), including efgartigimod, rilzabrutinib, mezagitamab, and TAK-079. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_hanny_al_samkari
• #institution_massachusetts_general_hospital
• #event_ash_2022
• #format_interview
• #subject_immune_thrombocytopenia
• #subject_rare_diseases
• #field_treatment
• #field_immuno_oncology
• #field_trial_updates
• #medicines_efgartigimod
• #medicines_iptacopan
• #medicines_rilzabrutinib
• #medicines_mezagitamab
• #medicines_antibodies
• #btk_inhibitor
• #complement
• #plasma_cells
• #medicines_tak_079
• #subject_non_malignant